At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 395 enrolled
Drug / intervention
Ingenol mebutate gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm2 on the Chest in Subjects With Actinic Keratosis
In Brief
A Phase 2 clinical trial evaluating Ingenol mebutate gel and placebo for Actinic Keratosis. Completed, enrolled 395 participants across 1 site.
Detailed Summary
To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or 3 consecutive days compared to vehicle gel
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartApr 2013
Primary CompletionAug 2014
TodayJul 2026
First PostedMar 28, 2013
Enrollment StartApr 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.3 years ago
Interventions
Ingenol mebutate geldrug
placebodrug